MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- SUN PHARMA
SUN PHARMA Share Price (SUNP)
Here is the latest stock price and chart of Sun Pharma. For more details, see the Sun Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Dec 10, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)427.50 | Open (Rs) 429.90 | High (Rs) 435.75 | Low (Rs) 425.50 |
| % Change0.12 | Volume 395,042 | Value (Rs) 169,907,912 | 52-Week H/L 484.10 / 350.40 |
| Live NSE Quotes | Dec 10, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)427.65 | Open (Rs) 429.60 | High (Rs) 435.75 | Low (Rs) 425.30 |
| % Change0.15 | Volume 5,578,960 | Value (Rs) 2,401,847,381 | 52-Week H/L 484.25 / 344.55 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 20.16 | P/E Ratio (x) 21.21 | Market Cap (Rs m) 1,028,886.91 | P/BV (x) 2.48 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
Listen In: Our Investor Hour Podcast Connects You with the World's Most Successful Investors
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
SUN PHARMA Share Price Today:
SUN PHARMA last traded price was up 0.1% to Rs 427.5 on the BSE. On the NSE, SUN PHARMA last traded price was up 0.2% to Rs 427.7. The total volume of shares traded was 6.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.8%. And the benchmark S&P BSE SENSEX was at 40,239.9 (down 0.6%).
Over the last 30 days, the SUN PHARMA share price is up 1.4%. And over the last one year, SUN PHARMA share price is up 7.2%.
|
| |
Today's Market
Sensex Ends 248 Points Lower; Power and IT Stocks Witness Selling(Closing)
Indian share markets fell sharply during closing hours today and ended deep in the red. The BSE Sensex stood lower by 248 points, while the NSE Nifty closed down by 81 points.
Related Views On News
SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)
Aug 14, 2019 | Updated on Aug 14, 2019For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Could this Smallcap Be the Next Page Industries? (Profit Hunter)
Nov 27, 2019A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.
A Simple, 7-Step Checklist for Your Trading Success
Dec 4, 2019What we can learn from one of the greatest traders to have ever lived.
Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market? (Profit Hunter)
Nov 28, 2019Should you invest in growth stocks or value stocks to make strong returns in this market?
The Best Trading Strategy for Fast Profits
Nov 29, 2019Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.
This PSU Turned into a Rare 100 Bagger. Others May Follow. (The 5 Minute Wrapup)
Nov 27, 2019The lowest hanging fruit for government to raise capital would be to sell off stakes in non-critical PSUs.
MoreTRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 5-YR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.